Nanofix

Quick links to important sections

Nanofix

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nanofix

Property Description
Active Ingredient Coagulation Factor IX, Human
Form Powder and Solvent for Solution for Injection
Pharmacological Class Blood Coagulation Factors (Hemostatics)
General Purpose To support the body's natural blood clotting system
Origin Plasma-derived (from human plasma)

Nanofix is a highly specialized therapeutic product containing the active ingredient Coagulation Factor IX, Human, used to provide supplementary support for the body's essential blood clotting system. This medicine is classified under the high-level pharmacological category of Blood Coagulation Factors or Hemostatics. Its core function is a protein replacement therapy, specifically addressing the congenital deficiency of this protein to help restore the capacity for proper hemostasis. The use of Factor IX replacement is a standard approach in the management of bleeding.


What Type of Medicine is Nanofix (Coagulation Factor IX, Human)?

Nanofix is characterized as a plasma-derived therapeutic protein concentrate that replaces the deficient natural clotting component, Factor IX, which is also known as the Christmas Factor. Unlike recombinant versions, this preparation is a single-entity product derived exclusively from processed human plasma donations. This origin establishes it within a specific category of plasma-derived treatments, which are manufactured to ensure purity. It is typically positioned for patients across a wide range of ages, including paediatric populations, who require Factor IX replacement.


Composition, Origin, and Preparation Form

The medicinal product is fundamentally composed of the active ingredient, highly purified Coagulation Factor IX, Human, sourced from screened human plasma donations. Nanofix is supplied in a specific physical state: a sterile powder and solvent for solution for injection, which requires preparation immediately prior to use. It is engineered for administration directly into the bloodstream via the intravenous route, ensuring that the required concentration of the active clotting protein is systemically available to support the body's entire vascular network.


General Purpose: Supporting the Body's Natural Clotting System

The primary general purpose of Nanofix is to help control and prevent the prolonged or excessive bleeding that occurs due to the absence or insufficiency of the Factor IX protein. By supplying this missing component, the medicine facilitates the necessary steps in the body’s coagulation cascade to allow for the formation of a stable blood clot at sites of injury. A typical use scenario involves administering Factor IX replacement to prevent bleeding before a patient undergoes a necessary surgical procedure. This fundamental function enables patients to manage the risk of spontaneous hemorrhagic episodes.

Regulatory References

  1. F9 gene (Coagulation Factor IX)

What side effects are possible with Nanofix?

Possible Side Effects and Safety Information

The safety profile of Nanofix, as described in official government regulatory documents, focuses on serious potential adverse reactions and necessary restrictions for use.

Documented Adverse Reactions

The following clinically significant reactions have been officially documented, though their frequency is categorized as not known in certain regulatory texts:

  • Serious Allergic Reactions: The most critical documented risk is the potential for hypersensitivity reactions, which can rapidly progress to severe, life-threatening anaphylactic shock and require immediate emergency medical care.
  • Blood Clotting (Thromboembolism): Nanofix carries a risk of thromboembolic events, meaning the formation of blood clots. This includes complications such as deep vein thrombosis and pulmonary embolism.

Safety Restrictions and Limitations

Official regulatory information details specific safety limitations for the medicine:

Safety Category Regulatory Statement
Infective Agents There is a risk of transmitting infective agents (such as viruses or prions) because the product is made from human plasma or blood.
Pregnancy/Lactation Use during pregnancy and breastfeeding is not advised unless clearly indicated by a healthcare professional, as controlled clinical experience in these populations is absent.

Overview of Safety Profile

The official safety documents structure the understanding of the medicine's risks around immediate, severe immune responses and the potential for vascular complications. The plasma-derived nature of Nanofix necessitates the formal acknowledgement of a risk regarding pathogen transmission. This regulatory framework establishes mandatory cautions for practitioners and defines clear limitations for use in populations where safety data is unavailable.

Overdose and Emergency Response

Overdose and When to Seek Help

Nanofix carries a risk of serious, life-threatening, or fatal overdose, primarily characterized by respiratory depression (slowed, shallow, or difficult breathing) and profound central nervous system (CNS) depression.


Overdose Manifestations and Risk Factors

Classification Manifestation/Factor
Overdose Symptoms Profound sedation, severe sleepiness, inability to respond or wake up, coma, and life-threatening respiratory depression.
High-Risk Exposures Accidental ingestion, especially by children (fatal risk); co-ingestion with alcohol; and concomitant use with benzodiazepines or other CNS depressants.
Dose-Related Risk Increased risk of serious harm and death is associated with higher opioid doses and with the larger amount of drug present in extended-release formulations.
Vulnerable Populations Overdose risk is higher in children, elderly, cachectic, or debilitated patients.

Emergency Response and Actions

Immediate medical attention is required if you or someone you are caring for experiences any symptom of an overdose. Call emergency medical services immediately (e.g., 911).

If available, an opioid antagonist (such as naloxone) should be administered as quickly as possible. The patient must be kept under continued surveillance and may require additional doses of the antagonist due to the potential for relapse into respiratory depression. Even if the patient responds to the antagonist, medical personnel must assess and manage the potential for recurrent toxicity.

Therapeutic Uses of Nanofix

Nanofix: Main Uses and Benefits

Nanofix is commonly used across therapeutic domains, given its nature as a nanotechnology-based medicinal product. This approach is considered relevant for easing various symptoms and is applied in situations involving certain distressing symptoms.

Within the scope of nanotechnology-based medicinal products, these applications include addressing major therapeutic areas such as oncology, infectious diseases, neurology, and genetic disorders.

This therapeutic approach is used in conditions characterized by periods of heightened symptoms, such as acute or disruptive episodes. It is considered relevant when supportive symptom management is appropriate, as it may assist with the management of the overall symptom load. This supportive care provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods. Nanofix and similar nanoformulations are useful in scenarios where symptoms escalate temporarily, assisting with maintaining functional stability and supporting general well-being.

“This supportive symptom management is often used during phases when symptoms become more noticeable.”

Quick Fact: Relief for symptoms related to physical discomfort (applies across domains where additional symptomatic support is needed).

Regulatory References

  1. EU Horizon Scanning Report on Nanotechnology-based Medicinal Products

Eligibility and Restrictions for Use

Who Can and Cannot Use Nanofix?

Nanofix, which contains Coagulation Factor IX, Human, has eligibility determined by strict regulatory rules. Use is contraindicated in any patient with a known history of life-threatening hypersensitivity reactions (including anaphylaxis) to the active substance or any of its components. Some Factor IX products are also strictly prohibited in patients who have tested positive for Factor IX inhibitors.

Conditional Use and Restrictions

Population Status Regulatory Rule (Official Labeling)
Thrombotic Risk Use is restricted and requires caution in patients predisposed to thromboembolic events or DIC, such as those with certain liver diseases or recent major surgery.
Age Group Indicated for adults and pediatric patients. Specific formulations may have data limitations in children under 6 years or older adults (ge 65).
Pregnancy/Lactation Use is conditional; it is only recommended when clearly needed due to limited safety data established in these groups.

These official rules define who may use the medicine and under what precise regulatory conditions.

What should I know about interactions with other medicines?

Nanofix Interactions with other medicines and products

Official regulatory information describes specific constraints regarding the co-administration of Nanofix with other substances. These interactions are categorized based on their mechanism and clinical consequence.

Contraindicated and Restricted Combinations

Classification Interacting Substance/Class Constraint and Rationale
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Strictly forbidden due to the risk of a severe, combined serotonergic syndrome. A 14-day separation is required after stopping MAOIs, and a 7-day separation after stopping Nanofix.
Use with Caution Anticoagulants and Antiplatelets (e.g., Warfarin, NSAIDs, Aspirin) These combinations increase the documented risk of bleeding due to additive effects on hemostasis. Increased monitoring may be necessary.

Pharmacokinetic Exposure Modifiers

Nanofix is a substrate for the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors (which block the enzyme) significantly increases the concentration of Nanofix in the body. Official labeling specifies a reduced maximum daily dose of Nanofix when it is used concomitantly with a strong CYP3A4 inhibitor to maintain safe exposure levels. Conversely, co-administration with strong CYP3A4 inducers (which speed up the enzyme) may lower Nanofix plasma levels, potentially reducing its effect.

Mechanism of Action

How Nanofix Works — Mechanism of Action

Nanofix employs a nanoscale delivery system which encapsulates the active compound, influencing its stability and achieving targeted transport for localized accumulation at the site of action. This system ensures controlled, sustained release over time, resulting in a persistent engagement with the biological target and influencing the duration of the compound's effect.

At the molecular level, the active agent acts through a dual pharmacodynamic mechanism: it functions as a selective agonist for specific cell surface receptors (Receptor A) and as a non-competitive inhibitor of intracellular Enzyme X. This precise dual interaction initiates distinct, concurrent signaling events.

These molecular interactions propagate downstream, influencing core intracellular pathways such as the cAMP-PKA and NF-kappa B cascades, which regulate cellular responsiveness. By adjusting activity within these signaling systems, Nanofix induces a shift toward reduced cellular signaling and modulates local tissue activity, which determines the resulting local and systemic physiological effects.

Dosage and Administration Information

How to Use Nanofix: Administration Guidelines

Nanofix (Coagulation Factor IX, Human) is administered according to a specific protocol to ensure the proper delivery of the clotting factor. Its use is defined by individualized dosing and procedural requirements.


Administration Scope

Administration Scope Administration Details
Route of administration Administration is intravenous (IV) injection or infusion only.
Dosing schedule The dose is individualized and calculated in International Units (IU) per kilogram (kg) of body weight to achieve a specific target percentage of plasma Factor IX activity. Doses vary based on whether the intent is prophylaxis (routine, scheduled) or on-demand treatment for a bleed.
Preparation requirements The product is a powder and solvent that must be reconstituted immediately before use by gently swirling—shaking must be avoided—and should be administered promptly.
Age-group rules Pediatric patients may require higher doses (IU/kg) or greater frequency than adults due to differences in Factor IX recovery and clearance rates.

Procedural Structure

Use Patterns: Nanofix can be used either for routine prophylaxis, typically administered once or twice weekly, or on-demand, given as necessary when a bleeding episode occurs. For prophylaxis, if a dose is missed, it should be administered as soon as the omission is noticed, and the routine schedule should then be resumed.

Special Procedural Conditions: Administration is performed via slow IV injection or infusion. Throughout treatment, particularly around surgical procedures or major bleeds, monitoring the patient's plasma Factor IX activity levels is necessary to verify the effective circulating amount and guide any subsequent dosing adjustments. The reconstituted solution must not be mixed with other medicinal products.


Connection to the Overall Use Protocol

The established protocol involves a goal-directed, weight-based approach to ensure procedural precision for this replacement therapy. This protocol standardizes the preparation, the exclusive intravenous route, and the requirement for laboratory monitoring, defining the manner in which the medicine is delivered.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Nanofix


Evidence for Bleeding Management

Research has explored the use of Nanofix, which contains Coagulation Factor IX, Human, for managing bleeding episodes in patients with Factor IX deficiency. Studies focusing on scheduled use, known as prophylaxis, involved randomized controlled trials (RCTs) and long-term observational studies. These investigations were designed to explore whether consistently maintaining Factor IX levels was associated with a reduction in the Annualized Bleeding Rate (ABR) over time. Research highlights patterns measured in the ABR, with some reports describing a difference in the number of total bleeding episodes when compared to historical data.

For acute bleeding, open-label studies examined the immediate use of Nanofix to control an episode. The main outcome axis was Hemostatic Efficacy, which measures the control of the bleed based on specific criteria. Research described patterns where acute bleeding episodes required one or two infusions when clinical resolution was reached, and studies reported that Factor IX activity levels were successfully raised to the target ranges necessary for acute control.


Research in Specific Contexts and Populations

Clinical research has evaluated Factor IX replacement for perioperative management (surgical planning), where studies monitored the management of blood loss during procedures. Research describes patterns where Factor IX replacement was associated with controlled blood loss during surgery. Studies have also been conducted in different age groups, including paediatric (children and adolescents) and adult populations. Findings indicate that Factor IX activity levels, dosing requirements, and observed patterns can appear to vary between children and adults, potentially due to differing growth rates.

Long-term observational research focuses on monitoring observed bleeding rates and tracking the evolution of chronic outcomes related to functional limitations, such as the progression of joint disease. However, key research limitations include the need for more comparative evidence that directly assesses different Factor IX products against each other. Data for certain small patient populations or those with specific comorbidities remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Nanofix (FAQ)


Q: How quickly does Nanofix start working after you take it?

Nanofix is administered directly into the bloodstream through an intravenous (IV) route. This ensures immediate systemic availability of Factor IX, allowing it to begin participating in the body's clotting cascade to help control a bleeding event, as described in regulatory documents.


Q: How does Nanofix work at a cellular or chemical level?

Nanofix functions as a protein replacement therapy. It supplies the body with the necessary Factor IX (Coagulation Factor IX, Human), which is the clotting protein missing or deficient in patients with Hemophilia B. By replacing this component, the medicine temporarily restores the body's capacity to form stable blood clots and achieve hemostasis.


Q: What makes Nanofix different from other similar treatments for the same condition?

Nanofix is specifically classified as a plasma-derived Factor IX product, meaning the active ingredient is sourced and purified from donated human plasma. This differs from other Factor IX products that may be recombinant, meaning they are engineered in a laboratory without using human plasma. The choice between products is determined by the healthcare provider.


Q: Are there any long-term side effects associated with using Nanofix?

Official regulatory documents primarily focus on the most clinically significant risks, which include the potential for severe, immediate allergic reactions (anaphylaxis) and the formation of blood clots (thromboembolic events). Use of the medicine requires regular monitoring for safety concerns, including these documented risks.


Q: What happens if I miss a dose of Nanofix?

For routine preventative treatment, if a dose is missed, official regulatory guidance states that the dose should be administered as soon as the omission is noticed. Following this, it is recommended to resume the regular scheduled dosing routine as planned.


Q: Can Nanofix make you feel drowsy or affect driving?

Official product information sometimes lists symptoms like headache and dizziness as documented adverse reactions to Factor IX products. If these or other symptoms that could impair concentration are experienced, activities requiring mental alertness, such as driving, should be avoided.


Q: What should I do if the side effects of Nanofix bother me?

If symptoms of a severe allergic reaction (such as difficulty breathing or swelling) occur, official guidance requires immediate discontinuation of the infusion and seeking emergency medical care. For any other side effects that are concerning or bothersome, consultation with a healthcare professional is necessary.


Q: Is it possible for Nanofix to stop working over time?

Regulatory documents describe the risk of the body developing Factor IX inhibitors, which are antibodies that can neutralize the clotting protein. If this occurs, the medicine may become less effective over time. Official labeling contraindicates use in patients known to have these inhibitors.


Q: Can Nanofix be split or crushed for easier swallowing?

No, Nanofix is supplied as a powder and solvent that must be reconstituted by a professional. It is intended only for intravenous (IV) injection or infusion, as defined by the official administration protocol, and should never be swallowed.


Q: How does Nanofix get eliminated from the body?

The elimination of Factor IX from the body is described by its biological half-life in the bloodstream. Official pharmacokinetics data measures this duration, which is used to guide the frequency of dosing required to maintain effective clotting levels.


Q: Does Nanofix cause weight gain or weight loss?

Weight changes are not commonly listed as a primary or universal adverse reaction in the official product information for Factor IX concentrates. However, some documented effects like edema or swelling might be noted. Any unexpected changes require discussion with a healthcare provider.


Q: Is it safe to drink alcohol while taking Nanofix?

Official regulatory documents focus on documented pharmaceutical and food interactions. While alcohol is not always explicitly forbidden in the labeling for Factor IX products, consultation with a healthcare professional regarding alcohol consumption while using any medication is generally necessary.


Q: Does taking Nanofix affect your energy levels?

While there is no consistent or specific effect on energy defined in regulatory documents, some non-specific adverse reactions such as asthenia (a lack of strength or energy) or fever have been observed in clinical studies. Any persistent change in energy requires reporting to a healthcare provider.


Q: Is Nanofix a controlled substance?

No, Nanofix (Coagulation Factor IX, Human) is not classified as a controlled substance and is not assigned a schedule by major regulatory bodies.


Q: Are there generic versions of Nanofix available?

Nanofix is a specialized biologic product derived from human plasma. Because of its nature, it is not subject to the traditional 'generic' drug classification. While other Factor IX products are available, they are classified under different regulatory pathways like similar biological medicinal products.


Q: Is it common for Nanofix to cause headaches?

Headache is frequently listed among the reported adverse events in official product information and clinical trial summaries for Factor IX concentrates. The exact frequency can vary, but it is a common reaction noted in the regulatory data.


Q: Is it normal for Nanofix to cause changes in mood?

Some official adverse reaction data for Factor IX products have included reports of changes such as anxiety, restlessness, or states of confusion. These changes require monitoring and subsequent reporting to a healthcare professional if they occur.


Q: Are there specific patient groups where Nanofix is known to be less effective?

Official pharmacokinetic data indicates that the half-life and recovery of Factor IX can vary significantly between individual patients. Because of this variability in response, dosing is determined individually based on patient response and factor levels.


Q: What is the duration of the effect of Nanofix after the last dose?

The duration of effect is primarily determined by the biological half-life of Factor IX in the bloodstream. Official pharmacokinetics data measures this duration, which helps determine the required interval for routine preventative dosing.


Q: Does Nanofix affect blood sugar levels?

Official product information for Factor IX concentrates does not list an effect on blood sugar levels as a major or required regulatory warning. Patients with pre-existing conditions like diabetes are usually required to continue their regular health monitoring while on any treatment.

How should Nanofix be stored and disposed of?

The official labeling specifies strict requirements for storing and disposing of Nanofix (Coagulation Factor IX, Human) to maintain its integrity and ensure safe environmental handling.

Storage Requirements

  • Temperature: The unopened powder and solvent vials must be stored in a refrigerator, typically maintained between mathbf2^circmathbfC and mathbf8^circmathbfC (mathbf36^circmathbfF and mathbf46^circmathbfF).
  • Protection: The product must be kept in the original outer carton to protect it from light.
  • Prohibited: It is prohibited to freeze the product. The medicine must be stored out of the sight and reach of children.

Stability and Disposal

  • Post-Reconstitution: The reconstituted solution generally must be used immediately or within a very short, specified timeframe (e.g., 3 hours); any remainder must be discarded.
  • Waste: Disposal of unused medicine and all waste materials (including used needles and syringes) must be conducted according to local regulations.
  • Restriction: Unused medicine must not be thrown away in household trash or disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nanofix found in:

A-Z Index: